Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, December 05 2019 - 09:00
Biocon Biologics Takes Forward its Mission to Unlock Universal Access to Insulins Globally
BUSAN, South Korea, December 5, 2019 /PRNewswire-AsiaNet/ --

Biocon Biologics, a fully integrated 'pure play' global biosimilars 
organisation, is taking forward its mission of unlocking affordable access to 
quality insulins for people with diabetes across the world. As a credible, 
global insulins player, it is committed to address the growing healthcare 
challenges associated with diabetes worldwide and is driven by its mission to 
enable affordable access.

Even as we near the 100th anniversary of the discovery of insulin, lack of 
equitable access to affordable insulin remains a key impediment to successful 
treatment for diabetes, leading to co-morbid complications and premature 
deaths. Diabetes currently affects over 463 million people worldwide and is 
projected to reach 578 million by 20301. 

Biocon Biologics has taken the lead to enable affordable access to insulins for 
patients across the world to ensure that people with diabetes who need insulins 
must get them. Pursuing an innovation strategy that is rooted in affordability, 
Biocon has cumulatively supplied over 2 billion doses of biosimilar insulins to 
patients globally over the last 15 years.

In September 2019, the Company made an announcement to enable universal access 
to recombinant human Insulin (rh-Insulin), by offering it at less than 10 US 
cents / day for Governments in LMICs. 

Kiran Mazumdar Shaw, Chairperson & MD, Biocon, said: "At Biocon, we are guided 
by the conviction that a lifesaving product like insulin cannot be priced out 
of the reach of those that need it on an everyday basis. We are committed to 
reducing the price of our insulin even further through partnerships with 
agencies like WHO, UNAIDS & others in order to break the barrier to access in 
certain geographies which are too poor to deal with the challenge of Diabetes 
on their own."  

Taking ahead its commitment to provide Universal Access to high quality 
insulins, Biocon Biologics made its debut at the ongoing International Diabetes 
Federation (IDF) Congress at Busan, South Korea, being held from December 2-6, 

Christiane Hamacher, CEO, Biocon Biologics, said: "In the run-up to the 100th 
anniversary of insulin, Biocon Biologics has embarked on a mission to unlock 
universal access to high quality insulin, guided by the conviction that a 
lifesaving product like this needs to be accessible to patients globally, both 
in emerging and developed countries. Our participation at the IDF Congress 2019 
is aimed at addressing current issues around insulin access, especially 
opportunities and value offered by biosimilars, how to achieve equitable care 
and sustaining India's role as pharmacy to the world. In line with our 
aspiration to reach 'one in five' insulin-dependent people with diabetes 
globally, we want to work closely with key stakeholders worldwide to find ways 
to ensure that insulin reaches those who need them the most."

Read More: 


MEDIA RELATIONS: Seema Ahuja, Sr. VP & Global Head, Corporate Communications, 
+91-80-2808-2222, +91-99723-17792,  

Source: Biocon Biologics